The latest announcements from JelikaLite, a medical technology company with focus on pediatric neurological health using non-invasive novel therapies.

JelikaLite has been granted Breakthrough Device Designation from the FDA for our Cognilum System – an individualized, non-invasive, investigational technology for the reduction of symptoms of moderate to severe autism spectrum disorder in pediatric patients.

JelikaLite’s StartEngine campaign is live! Since launching our campaign, our team has been blown away by the positive response we’ve received from our community. We are proud of our vision to revolutionalize the pediatric autism treatment and improve the lives of millions of families. We’re so excited to have you on this journey with us.

Dr. Eugenia Steingold presented at The BRAIN Foundation’s Synchrony Conference on translational autism. Dr. Steingold discussed transcranial photobiomodulation and the results of JelikaLite’s recent double-blind, placebo-controlled clinical trial, with children aged 2 – 6

JelikaLite presents results of the pivotal clinical trial at Rutgers University Center for Autism Research, Education, and Services (RUCARES)

JelikaLite presents results of the pivotal clinical trial at American Academy of Child & Adolescent Psychiatry.

After receiving the largest batch of applications in the competition’s history, Upstate Medical University’s CNY Biotech Accelerator (CNYBAC) has selected its 2021 Medical Device Innovation Challenge (MDIC) cohort – JelikaLite was one of the 6 selected teams.

Katya Sverdlov (CEO of JelikaLite) spoke with NYS Manufacturing Now about the company’s efforts to light the way to a brighter future.

Brain Scientific Announces Collaboration with JelikaLite in New Clinical Trial.